Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leela Barham

Latest From Leela Barham

Patient Groups Want More Say In Talks On New UK Pricing Deal

The Association of the British Pharmaceutical Industry has welcomed calls from three patient group umbrella organizations to be more involved as the UK government negotiates with the ABPI on a successor to the 2019 voluntary pricing scheme.

Europe United Kingdom

Legal Challenge Could Put UK Drug Pricing Deal At Risk

The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.

Europe United Kingdom

Mixed Support For ABPI's UK Price Scheme Proposals

The UK pharma industry body has set out bold proposals for a new drug pricing agreement from 2024, but not everyone is convinced. Generics companies are pressing for more of a say in the negotiations, while patient groups want to know more about how the deal would help improve access to medicines.

Europe United Kingdom

Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme

Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.

Pricing Debate Regulation

Former NICE Exec Proposes New UK Fund For ‘High-Impact’ Drugs

Some of the rebates paid by drug companies to the government on their sales of medicines could be placed in a central fund to pay for drugs of “demonstrable benefit,” according to Andrew Dillon.

Europe United Kingdom

Freezing UK Statutory Scheme Rebate Could Cost UK Government Over £15m

Accepting the pharmaceutical industry’s request to keep the statutory scheme rebate rate at its current rate this year could cost the government dearly, but raising it as planned could be detrimental for UK life sciences.

Europe United Kingdom
See All